AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
PolyPid Appoints Dr. Nurit Tweezer-Zaks as Chief Medical Officer.
ByAinvest
Tuesday, Aug 12, 2025 8:11 am ET1min read
PolyPid has appointed Dr. Nurit Tweezer-Zaks as Chief Medical Officer, effective August 18, 2025. She will step down from the Board of Directors. Dr. Tweezer-Zaks brings extensive medical expertise and industry experience, making her well-suited to lead the company's medical strategy as it prepares for its NDA submission and advances its pipeline.
PolyPid (NASDAQ:PYPD), a late-stage biopharma company, has appointed Dr. Nurit Tweezer-Zaks as Chief Medical Officer, effective August 18, 2025. Dr. Tweezer-Zaks will step down from her current role on PolyPid's Board of Directors, which she has held since November 2023. This appointment comes on the heels of positive Phase 3 SHIELD II trial results and is a strategic move as the company prepares for its New Drug Application (NDA) submission.Dr. Tweezer-Zaks brings significant experience from her roles as CEO of MediCane Health Inc., CMO at aMOON Venture Capital Fund, and various positions at Sanofi. She has also practiced as a physician at Sheba Medical Center for 15 years. Her extensive background in medical and executive roles makes her well-suited to lead PolyPid's medical strategy.
"This appointment is a significant milestone for PolyPid," said Dikla Czaczkes Akselbrad, Chief Executive Officer of PolyPid. "Dr. Tweezer-Zaks' expertise and experience will be invaluable as we prepare for our NDA submission and advance our pipeline."
Dr. Tweezer-Zaks holds an M.D. and B.S. from Ben-Gurion University School of Medicine in Beer Sheva, Israel, and an M.B.A. from the Kellogg-Recanati International Executive MBA Program. She is excited to join PolyPid's executive team at this transformative moment for the company.
PolyPid's proprietary PLEX technology, which pairs with Active Pharmaceutical Ingredients (APIs) for precise drug delivery, is the foundation of its pipeline. Following positive phase 3 results, the company expects to submit its NDA for D-PLEX100, a lead product candidate for the prevention of abdominal colorectal surgical site infections, in early 2026. Additionally, the company has an innovative pipeline in oncology, obesity, and diabetes.
References:
[1] https://www.stocktitan.net/news/PYPD/poly-pid-appoints-dr-nurit-tweezer-zaks-as-chief-medical-w1flir72kdqr.html
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet